Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer
comparisons. Features of the tumor microenvironment heavily affect disease biology and …

Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC)
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …

Background: Circular RNAs (circRNAs) have been identified as essential regulators in a
plethora of cancers. Nonetheless, the mechanistic functions of circRNAs in Renal Cell …

Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic
clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared …

Background No approved systemic therapy exists for von Hippel-Lindau disease, an
autosomal dominant disorder with pleiotropic organ manifestations that include clear cell …

Background The use of cytoreductive nephrectomy (CN) selectively for patients who show a
favorable response to upfront systemic therapy may be an approach to select optimal …

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses
when combined with programmed death-1 inhibitors such as nivolumab. We report a single …

Purpose: The optimal sequence of cytoreductive nephrectomy and targeted therapy of
metastatic renal cell carcinoma is unclear. We compared overall survival between patients …